Minoxidil Patent Expiration

Minoxidil is Used for promoting hair regrowth in patients with hair loss. It was first introduced by Pfizer Inc in its drug Loniten on Approved Prior to Jan 1, 1982. Other drugs containing Minoxidil are Men'S Rogaine, Rogaine (For Women), Rogaine Extra Strength (For Men), Women'S Rogaine, Rogaine (For Men). 25 different companies have introduced drugs containing Minoxidil.


Minoxidil Patents

Given below is the list of patents protecting Minoxidil, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

NEW
Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Men's Rogaine US6946120 Pharmaceutical composition Apr 20, 2019

(Expired)

Kenvue Brands
Women's Rogaine US6946120 Pharmaceutical composition Apr 20, 2019

(Expired)

Kenvue Brands



Minoxidil's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List



Clinical Trials

Recent Clinical Trials on Minoxidil:

Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
Treatment of Androgenetic Alopecia in Men for 24 Weeks Eurofarma Laboratorios S.A. NA COMPLETED
(Sep 1, 2026)
PHASE3
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia Industrial Farmacéutica Cantabria, S.A. NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3
Minoxidil With or Without Low-Level Red-Light Therapy for Improving Chemotherapy-Induced Alopecia in Breast Cancer Patients Ohio State University Comprehensive Cancer Center NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2
Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon Duke University NA RECRUITING
(Apr 1, 2026)
PHASE1
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia. Eurofarma Laboratorios S.A. NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE3
Comparative Study of Microneedling With Topical Minoxidil 5% ± NB-UVB in Stable Vitiligo" Sohag University NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2


Minoxidil Generic API Manufacturers

Several generic applications have been filed for Minoxidil. The first generic version for Minoxidil was by Watson Laboratories Inc and was approved on Mar 3, 1987. And the latest generic version is by Taro Pharmaceutical Industries Ltd and was approved on Jun 30, 2025.

Given below is the list of companies who have filed for Minoxidil generic, along with the locations of their manufacturing plants worldwide.


Minoxidil News

Exploring the Journey from Weight Reduction to Hair Thinning: The Quest for the Next Major Breakthrough - BioSpace

10 Nov, 2025

Ongoing Discussion Surrounding Patents for Second Medical Uses - Mondaq

22 Apr, 2025

See More